

Paxman publishes newsletter on clinical study with Black and Latina cancer patients with textured hair

Today, Paxman publishes the October issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights a clinical study at Montefiore Einstein Cancer Center in New York City (MECC) which will use Paxman Scalp Cooling to investigate if the treatment can help Black and Latina women with textured hair types to mitigate chemotherapy-induced alopecia (CIA). The trial will also determine which women are at a high risk of permanent hair loss as a result of CIA by trying to identify biomarkers for cellular and genetic determinants.

The newsletter also includes information on the release of whitepapers from the successful Scalp Cooling Summit earlier this year, the launch of Paxman's redesigned company website with pages for local distributors, the latest episode of the Changing the Face of Cancer Podcast on a clinical study at Dana Farber Cancer Institute evaluating scalp cooling for patients with metastatic cancer, the order flow of the month including equipment to Europe, Pakistan, the UK and the US, and supported events and media coverage featuring Paxman during Breast Cancer Awareness Month.

To read the newsletter and subscribe for upcoming issues, follow this link:

<https://bit.ly/paxoct22en>

Paxman's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on Paxman's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,400 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company's Certified Adviser.

Attachments

[Paxman publishes newsletter on clinical study with Black and Latina cancer patients with textured hair](#)